Sanofi (SNY)
48.37
-0.09
(-0.19%)
USD |
NASDAQ |
Nov 13, 16:00
48.27
-0.10
(-0.21%)
After-Hours: 05:31
Sanofi Enterprise Value : 126.67B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 126.67B |
| November 12, 2026 | 126.89B |
| November 11, 2026 | 126.82B |
| November 10, 2026 | 126.33B |
| November 09, 2026 | 126.07B |
| November 06, 2026 | 123.44B |
| November 05, 2026 | 123.13B |
| November 04, 2026 | 124.49B |
| November 03, 2026 | 119.29B |
| November 02, 2026 | 119.83B |
| October 30, 2026 | 116.89B |
| October 29, 2026 | 113.95B |
| October 28, 2026 | 111.79B |
| October 27, 2026 | 110.94B |
| October 26, 2026 | 110.70B |
| October 23, 2026 | 110.23B |
| October 22, 2026 | 111.11B |
| October 21, 2026 | 108.71B |
| October 20, 2026 | 109.75B |
| October 19, 2026 | 105.31B |
| October 16, 2026 | 107.83B |
| October 15, 2026 | 107.05B |
| October 14, 2026 | 105.79B |
| October 13, 2026 | 104.21B |
| October 12, 2026 | 105.72B |
| Date | Value |
|---|---|
| October 09, 2026 | 106.52B |
| October 08, 2026 | 106.91B |
| October 07, 2026 | 106.84B |
| October 06, 2026 | 105.28B |
| October 05, 2026 | 105.16B |
| October 02, 2026 | 106.16B |
| October 01, 2026 | 107.98B |
| September 30, 2026 | 109.34B |
| September 29, 2026 | 108.15B |
| September 28, 2026 | 109.21B |
| September 25, 2026 | 109.05B |
| September 24, 2026 | 108.63B |
| September 23, 2026 | 110.38B |
| September 22, 2026 | 112.44B |
| September 21, 2026 | 112.42B |
| September 18, 2026 | 112.37B |
| September 17, 2026 | 113.97B |
| September 16, 2026 | 112.64B |
| September 15, 2026 | 112.18B |
| September 14, 2026 | 114.44B |
| September 11, 2026 | 113.08B |
| September 10, 2026 | 112.95B |
| September 09, 2026 | 113.27B |
| September 08, 2026 | 114.01B |
| September 04, 2026 | 116.65B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 598.40B |
| GSK Plc | 128.16B |
| Johnson & Johnson | 715.26B |
| Eli Lilly & Co. | 1.403T |
| Merck & Co., Inc. | 408.57B |
Enterprise Value Related Metrics
| Earnings Yield | 4.01% |
| Operating Earnings Yield | 12.43% |
| Normalized Earnings Yield | 7.102 |